Ibere Pharmaceuticals
IBER-WT
New York Stock Exchange0.00
USD
- -
- -
CIK
0001835205
Return %
Stock
S&P500
1Y
-98.21
26.84
3Y
-98.21
77.03
5Y
-98.21
80.55
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Sector
- Financial Services
- Industry
- Shell Companies
- Address
- CIK
- 0001835205
- Similar Companies
- Business
- Ibere Pharmaceuticals (NYSE: IBER-WT) operates as a blank check company, or special purpose acquisition company (SPAC), with no significant ongoing business operations; it pursues mergers, amalgamations, share exchanges, asset acquisitions, share purchases, reorganizations, or similar combinations targeting pharmaceutical and life sciences firms, particularly those with strong international brands. Incorporated in 2020 as a Cayman Islands exempted company and headquartered in Philadelphia, Pennsylvania, the firm completed an upsized $138 million initial public offering in March 2021, offering units comprising Class A ordinary shares and warrants, which commenced separate trading shortly thereafter. In February 2023, Ibere announced the redemption of all outstanding public shares at approximately $10.17 per share and its subsequent voluntary dissolution effective March 2, 2023, after failing to complete a business combination within the required timeframe; trading of its shares ceased on March 1, 2023, marking the cessation of all operations except for winding up affairs under Cayman Islands law. The IBER-WT warrants, detached from the original units, reflect this terminated status with minimal trading activity and negligible value.